INVO Bioscience Files 10-K/A Amendment for Fiscal Year 2022
Ticker: IVF · Form: 10-K/A · Filed: Mar 27, 2024 · CIK: 1417926
Sentiment: neutral
Topics: 10-K/A, INVO Bioscience, SEC Filing, Financial Reporting, Amendment
TL;DR
<b>INVO Bioscience has filed an amended 10-K for the 2022 fiscal year, providing updated financial reporting information.</b>
AI Summary
INVO Bioscience, Inc. (IVF) filed a Amended Annual Report (10-K/A) with the SEC on March 27, 2024. INVO Bioscience, Inc. filed an amended 10-K report for the fiscal year ended December 31, 2022. The company's common stock trades under the symbol 'INVO' on The Nasdaq Stock Market LLC. INVO Bioscience is incorporated in Nevada and headquartered in Sarasota, Florida. The filing indicates the company is a smaller reporting company, not a large accelerated or accelerated filer. This is an amended filing (Amendment No. 2) submitted on March 27, 2024.
Why It Matters
For investors and stakeholders tracking INVO Bioscience, Inc., this filing contains several important signals. This amended filing ensures the company's financial disclosures for the 2022 fiscal year are up-to-date and compliant with SEC regulations. As a smaller reporting company, this filing provides key financial and operational details relevant to investors assessing INVO Bioscience's performance and outlook.
Risk Assessment
Risk Level: low — INVO Bioscience, Inc. shows low risk based on this filing. The filing is an amendment (10-K/A), suggesting potential corrections or updates to previously filed information, but the core data for the fiscal year ending 2022 is being presented.
Analyst Insight
Review the specific amendments within this 10-K/A filing to understand any changes to INVO Bioscience's financial position or disclosures for the 2022 fiscal year.
Key Numbers
- 2022-12-31 — Fiscal Year End (Reported fiscal year end)
- 2024-03-27 — Filing Date (Date of amendment submission)
- 001-39701 — SEC File Number (Registrant's SEC file number)
Key Players & Entities
- INVO Bioscience, Inc. (company) — Filer name
- Nasdaq Stock Market LLC (company) — Exchange where common stock is registered
- Sarasota, Florida (location) — Principal executive office location
- 2022-12-31 (date) — Fiscal year end
- 2024-03-27 (date) — Filing date
FAQ
When did INVO Bioscience, Inc. file this 10-K/A?
INVO Bioscience, Inc. filed this Amended Annual Report (10-K/A) with the SEC on March 27, 2024.
What is a 10-K/A filing?
A 10-K/A is a amendment to a previously filed annual report, correcting or updating financial statements or disclosures. This particular 10-K/A was filed by INVO Bioscience, Inc. (IVF).
Where can I read the original 10-K/A filing from INVO Bioscience, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by INVO Bioscience, Inc..
What are the key takeaways from INVO Bioscience, Inc.'s 10-K/A?
INVO Bioscience, Inc. filed this 10-K/A on March 27, 2024. Key takeaways: INVO Bioscience, Inc. filed an amended 10-K report for the fiscal year ended December 31, 2022.. The company's common stock trades under the symbol 'INVO' on The Nasdaq Stock Market LLC.. INVO Bioscience is incorporated in Nevada and headquartered in Sarasota, Florida..
Is INVO Bioscience, Inc. a risky investment based on this filing?
Based on this 10-K/A, INVO Bioscience, Inc. presents a relatively low-risk profile. The filing is an amendment (10-K/A), suggesting potential corrections or updates to previously filed information, but the core data for the fiscal year ending 2022 is being presented.
What should investors do after reading INVO Bioscience, Inc.'s 10-K/A?
Review the specific amendments within this 10-K/A filing to understand any changes to INVO Bioscience's financial position or disclosures for the 2022 fiscal year. The overall sentiment from this filing is neutral.
How does INVO Bioscience, Inc. compare to its industry peers?
INVO Bioscience operates in the medical device sector, specifically focusing on assisted reproductive technology (ART).
Are there regulatory concerns for INVO Bioscience, Inc.?
The filing is a standard SEC Form 10-K/A, an amended annual report required under the Securities Exchange Act of 1934.
Industry Context
INVO Bioscience operates in the medical device sector, specifically focusing on assisted reproductive technology (ART).
Regulatory Implications
The filing is a standard SEC Form 10-K/A, an amended annual report required under the Securities Exchange Act of 1934.
What Investors Should Do
- Analyze the specific changes and additions made in Amendment No. 2 to the 10-K filing.
- Review the company's status as a 'smaller reporting company' and its implications.
- Cross-reference this filing with previous reports to identify any significant shifts in financial or operational disclosures.
Key Dates
- 2022-12-31: Fiscal Year End — The period covered by the amended 10-K report.
- 2024-03-27: Filing Date — Date of submission for Amendment No. 2 to the 10-K.
Year-Over-Year Comparison
This is an amended filing (10-K/A) for the fiscal year ended December 31, 2022, indicating updates or corrections to previously submitted information.
Filing Stats: 1,180 words · 5 min read · ~4 pages · Grade level 12.9 · Accepted 2024-03-27 17:24:08
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share INVO The Nasdaq
- $0.64 — ice of the registrant's common stock of $0.64 on the NASDAQ as of that date. The nu
Filing Documents
- form10-ka.htm (10-K/A) — 55KB
- ex23-1.htm (EX-23.1) — 4KB
- ex31-5.htm (EX-31.5) — 5KB
- ex31-6.htm (EX-31.6) — 5KB
- 0001493152-24-011557.txt ( ) — 287KB
- invo-20221231.xsd (EX-101.SCH) — 3KB
- invo-20221231_lab.xml (EX-101.LAB) — 35KB
- invo-20221231_pre.xml (EX-101.PRE) — 23KB
- form10-ka_htm.xml (XML) — 7KB
SIGNATURES
SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K/A to be signed on its behalf by the undersigned, thereunto duly authorized on March 27, 2024. INVO Bioscience, Inc. Date: March 27, 2024 By: /s/ Steven Shum Steven Shum Chief Executive Officer (Principal Executive Officer)